Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027

Artiva Biotherapeutics, Inc.

Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
Cash, equivalents and investments $108.0M as of Dec 31, 2025, expected to fund operations into Q2 2027.
AlloNK for refractory RA: initial clinical response data from ≥15 patients expected H1 2026; FDA Fast Track granted.
Planned FDA interaction in H1 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.
Appointed Subhashis Banerjee, M.D. as CMO and Thad Huston as CFO; added two board members with immunology/commercial expertise.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Artiva Biotherapeutics, Inc. reported the year ended December 31, 2025 results: revenue zero, net income Net loss totaled $83.9 million.

Period: the year ended December 31, 2025
Revenue: zero
Net income: Net loss totaled $83.9 million
Result: reported results

Exact text from the filing

On March 10, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Artiva Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-100131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.